India’s Covid-19 vaccine COVAXIN: shows ‘encouraging results’ in trials

Covid-19 vaccine Covaxin human trials have been started in AIIMS Delhi and PGIMS Rohtak. The first part of phase 1 human trial has been completed at Post Graduate Institute Of Medical Sciences, Rohtak, Haryana.

The trial in PGIMS Rohtak began on July 17 and in AIIMS Delhi from July 20.

The first part of the phase-1 of vaccine trial (Covaxin) has been completed. 50 people across India were administered the vaccine and the results were encouraging. Six people were administered vaccine on Saturday under part of phase-1,” said the principal of PGIMS Rohtak, Dr Savita Verma.

Dr Verma, the principal investigator of the trial team said that her team got very encouraging results of phase 1 human trial and also informed that six people have been given the duty to control the second part of phase I trial.

Covaxin is India’s first coronavirus vaccine which is developed in collaboration with Bharat Biotech and ICMR.

Moreover, human trials will commence in nine other medical institutions in the country which have been selected by the Indian Council of Medical Research (ICMR).

Even the University of Oxford with AstraZeneca has also developed a vaccine which is supplied to many countries to treat Coronavirus patients.